Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (6.871.189 €): Förderung eines GMMA-basierten Impfstoffs gegen invasive nichttyphoide Salmonellose durch Phase-1-Studie in Europa und Afrika südlich der Sahara Hor 14.06.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
Förderung eines GMMA-basierten Impfstoffs gegen invasive nichttyphoide Salmonellose durch Phase-1-Studie in Europa und Afrika südlich der Sahara
Invasive non-typhoidal Salmonellosis (iNTS) is an important emerging Neglected Infectious Disease in resource-poor settings of sub-Saharan Africa (sSA). No vaccine is currently available. Estimated 263,000 iNTS deaths per year in <5 year olds, a 20% case fatality rate, difficult diagnosis and increasing antibiotic resistance strongly advocate for rapid development of an effective vaccine. Vacc-iNTS bridges the gap between preclinical and early clinical development of a novel vaccine against iNTS, based on GMMA (Generalized Modules for Membrane Antigens) from the most common African iNTS serotypes (Typhimurium and Enteritidis). The highly cost-effective GMMA-technology, developed by partner 2, is based on outer membrane blebs released by genetically modified bacteria. Clinical proof-of-concept for the GMMA-technology was achieved with a Shigella sonnei vaccine in European and African adults. In animals, iNTS-GMMA were highly immunogenic and induced antibodies with bactericidal activity against African iNTS strains. Simple, robust and scalable manufacturing processes for iNTS-GMMA, suited for sSA, have been developed. Vacc-iNTS proposes GMP manufacturing of clinical lots followed by a two-stage Phase 1 trial in healthy European and African adults to investigate safety and immunogenicity of the iNTS-GMMA vaccine. Analysis include serum antibody levels and functionality, cellular responses, transcriptomics and data integration through a systems biology approach. Sero-epidemiological analysis will be conducted to provide essential data for future Phase 2 and 3 trials. Vacc-iNTS will also strengthen a collaborative network of iNTS experts from academia, industry and non-profit including partners from disease-endemic countries of sSA. The network will generate data to accelerate further vaccine development, enhance awareness, drive advocacy and vaccine deployment in limited-resources disease-endemic countries, tackling major roadblocks in advancing a vaccine against iNTS.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Fondazione Achille Sclavo Organizzazione NON Lucrativa Di Utilita Sociale | 0,00 € |
| Glaxosmithkline Biologicals SA | 0,00 € |
| GSK Vaccines Institute FOR Global Health Srl | 1.576.515 € |
| Instituut Voor Tropische Geneeskunde | 31.297 € |
| Kenya Medical Research Institute | 107.575 € |
| Kwame Nkrumah University OF Science AND Technology Kumasi | 194.226 € |
| MMGH Consulting GmbH | 20.000 € |
| Sclavo Vaccines Association | 1.152.312 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 2.227.289 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 545.943 € |
| The University of Liverpool | 432.035 € |
| Universita Degli Studi Di Siena | 341.018 € |
| Universite Joseph KI-Zerbo | 192.980 € |
| University OF Malawi | 0,00 € |
| University OF Otago | 50.000 € |
Quelle: https://cordis.europa.eu/project/id/815439
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.